MedTrace Logo

Iloprost in Gas Exchange/Pulm Mechanics in Chronic Obstructive Pulmonary Disease (COPD)

NCT00561223 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2024-02-15

No results posted yet for this study

Summary

The investigators believe that iloprost will improve gas exchange in COPD patients with pulmonary hypertension.

Conditions

Interventions

DRUG

iloprost Inhalation

inhale 2.5 mg, repeat times one

DRUG

iloprost

inhaled 2.5 mg, repeat times one

Sponsors & Collaborators

  • University of Oklahoma

    lead OTHER

Principal Investigators

  • Gary T Kinasewitz, MD · University of Oklahoma

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-11-30
Primary Completion
2008-04-30
Completion
2012-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00561223 on ClinicalTrials.gov